The transcription factor MEF2C (Myocyte Enhancer Factor 2C) plays an established role in the early steps of myogenic differentiation. However, the involvement of MEF2C in adult myogenesis and in muscle regeneration has not yet been systematically investigated. Alternative splicing of mammalian MEF2C transcripts gives rise to two mutually exclusive protein variants: MEF2Ca2 which exerts a positive control of myogenic differentiation, and MEF2Ca1, in which the a1 domain acts as trans-repressor of the MEF2C pro-differentiation activity itself. However, MEF2Ca1 variants are persistently expressed in differentiating cultured myocytes, suggesting a role in adult myogenesis. We found that overexpression of both MEF2Ca1/a2 proteins in a mouse model of muscle injury promotes muscle regeneration and hypertrophy, with each isoform promoting different stages of myogenesis. Besides the ability of MEF2Ca2 to increase differentiation, we found that overexpressed MEF2Ca1 enhances both proliferation and differentiation of primary myoblasts, and activates the AKT/mTOR/S6K anabolic signaling pathway in newly formed myofibers. The multiple activities of MEF2Ca1 are modulated by phosphorylation of Ser98 and Ser110, two amino acid residues located in the a1 domain of MEF2Ca1. These specific phosphorylations allow the interaction of MEF2Ca1 with the peptidylprolyl isomerase PIN1, a regulator of MEF2C functions. Overall, in this study we established a novel regulatory mechanism in which the expression and the phosphorylation of MEF2Ca1 are critically required to sustain the adult myogenesis. The described molecular mechanism will represent a new potential target for the development of therapeutical strategies to treat musclewasting diseases. STEM CELLS 2016; 00:000-000
INTRODUCTION
Skeletal muscle regeneration and hypertrophy are key adaptive responses to both pathological and physiological stimuli. Both processes are sustained by a population of resident selfrenewing muscle stem cells, referred to as Satellite Cells (SC), located under the basal lamina [1] [2] [3] [4] . SC are quiescent in the adult steady state, when triggered by signals resulting from exercises or injuries, they become activated and give rise to a population of myogenic precursor cells (myoblasts) that proliferate, migrate and fuse with the host fibers or generate new myofibers leading to muscle growth/ repair. SC self-renewal also ensures the maintenance of a stem cell pool [5, 6] . During the myogenic progression of SC, a controlled balance between proliferation, differentiation and self-renewal is required, to assure efficient muscle repair and maintenance throughout life. The transcriptional control of these processes in vertebrates is mainly regulated by a handful of protein families, including the paired box transcription factors PAX3 and PAX7, the myogenic regulatory factors (MRFs), MYOD, MYOGENIN, MYF5, and MRF4, the Myocyte Enhancer Factor-2 (MEF2) transcription factors and the homeodomain transcription factors SIX [7] [8] [9] [10] [11] . In addition to their roles in the transcriptional activation of musclespecific genes, these proteins are involved in controlling cell cycle progression. Importantly, they are the ultimate targets of multiple signaling pathways activated by external cues and, by integrating these various signals, they determine the balance between muscle precursors proliferation and cell cycle exit. There are four MEF2 proteins (MEF2A, -B, -C, and -D) in vertebrates, their structures are tailored for receiving and responding to multiple signaling pathways that control their functions at several levels, including alternative splicing (AS) of the encoding transcripts and post-translational modifications [12] [13] [14] [15] [16] . It has been shown that skeletal muscle-specific deletion of Mef2 genes results in impaired muscle regeneration, however the involvement of MEF2 factors in the control of muscle growth and regeneration has not yet been systematically investigated [7, 8] . It has been reported that mutually exclusive AS of exons a1 and a2 in Mef2c and Mef2d transcripts is regulated during skeletal myogenesis and that inclusion of a2 exons in Mef2c and Mef2d transcripts is important to guarantee efficient myogenic differentiation in cultured myoblasts and in vivo respectively, whereas the a1 domains act as trans-repressors of MEF2 myogenic activity [15, 16] . However, the function associated with the a1 domains might be more complex, as the a11 isoforms (MEF2Ca1 splice variants) are persistently expressed in differentiating cultured myocytes [15] [16] [17] . Likewise, we observed that inclusion of the a1 exon in mouse Mef2c transcripts is upregulated in vivo in the early phases of muscle regeneration and is maintained during later stages of myogenesis, suggesting unexplored functions for this isoform during adult myogenesis. In addition to AS, covalent modifications such as phosphorylation, acetylation and sumoylation, are critical for modulating MEF2 function, however how these modifications are regulated during myogenesis in vivo is still unknown [18] [19] [20] [21] [22] . Finally, the function of MEF2C is widely regulated by its direct physical interaction with several coactivators and corepressors [23] . For instance, we had previously reported a regulatory mechanism that represses MEF2-dependent transcription in muscle precursors via physical interaction with the peptidyl-prolyl cistrans isomerase PIN1 [24] . The PIN1/MEF2C interaction requires phosphorylation of two serine residues, Ser98 and Ser110, that are located in the a1 domain, raising the question of how inclusion of the a1 exon in Mef2c transcripts, phosphorylation of Ser98 and Ser110 in the encoded a1 domain and interaction with PIN1 are coordinated for the regulation of MEF2C function in adult myogenesis in vivo. In order to elucidate the function of MEF2Ca1 in adult myogenesis, we have investigated the function of MEF2C protein variants in SC using both in vitro and in vivo approaches. In agreement with previous results [16] , we observed that the MEF2Ca2 isoform exhibits its myogenic activity also in vivo, moreover, we provide the first evidence of pro-hypertrophic and pro-regenerative activities of MEF2Ca1 in skeletal muscle mediated by multiple sequential mechanisms, including stimulation of SC expansion and subsequent terminal differentiation and activation of the PI3K/AKT-dependent protein synthesis pathway in adult myofibres. The switch between these multiple mechanisms is associated with phosphorylation of the Ser98 and Ser110 residues that regulates its interaction with PIN1. We thus conclude that, the timely inclusion of a1 exon in Mef2c transcripts and phosphorylation of the corresponding MEF2C isoform determines its protein interactions: integration of these mechanisms leads to a coordinated modulation of MEF2C function during adult myogenesis.
MATERIALS AND METHODS
Cell Lines, Primary Cultures, and Single Myofibers C2C12, COS1 and NIH 3T3 cells were maintained in DMEM/10% FBS. To induce C2C12 cells differentiation, confluent cells were maintained in DMEM/2% Horse Serum (HS). Primary cultures of SC were prepared from adult muscles of Pax3 GFP/1 mice as described [25] and grown in SC plating medium (40% F12/40% DMEM/20% FBS, Ultroser). DMEM, F12 and FBS Gibco were provided by Life Technologies, Thermofisher, https://www.thermofisher.com, FBS by Gibco, HS Hyclone by GE Healthcare, http://www.gelifesciences.com, Ultroser Biosepra by Pall Corporation, http://www.pall.com. Adult (4 weeks old) C57BL6 mice were killed by cervical dislocation, and the extensor digitorum longus (EDL) muscles isolated and digested in collagenase as described [26] . Myofibres and associated SC were isolated and cultured in suspension or in adhesion on matrigel-coated plates (BD) in SC plating medium. To promote differentiation of primary SC-derived myoblasts, after 4-5 days of culture they were kept in differentiation medium with low serum [27] .
Muscle Regeneration
Mouse studies were performed in accordance with the current version of the Italian Law on the Protection of Animals and approved by the local ethics committee. Tibialis anterior (TA) muscles of C57/BL6 mice (Charles River, http://www. criver.com/) were chemically injured using cardiotoxin (CTX) and after 2, 5 or 15 days of recovery, the injured and the controlateral control muscles were collected and used for protein and RNA extraction or embedded in OCT compound, frozen in isopentane cooled with liquid nitrogen and then sectioned (cross-section of 8 lm thickness) for immunofluorescence staining. To induce protein overexpression during muscle regeneration, both TA muscles were injured and, after 48 h of recovery, lentiviruses (multiplicity of infection-MOI-25) encoding MEF2C isoforms were injected into one of the regenerating TA muscles, while the contralateral was injected with an empty lentivirus. Muscle samples were collected at day 5 and 15 postinjury. Changes in distribution of fiber size was assessed measuring the cross-sectional area (CSA) of myofibers. Counting was performed using NIH ImageJ and the distribution of muscle-fibers CSA was obtained by ranking the fibers by size and the mean 6 SEM, the number of muscle fibers of n 5 3 animals was calculated for each size range.
Immunofluorescence and Bimolecular Fluorescence Complementation Assay
Isolated myofibers, muscle sections or plated cells were fixed with 4% paraformaldehyde, permeabilized (0.2% Triton X-100, 50 mM NH 4 Cl in PBS) and then blocked for 1 hour with 2% HS, finally incubated overnight at 48C with primary antibodies. Samples were stained with Hoechst (Sigma-Aldrich, Italy, Milan http://www.sigmaaldrich.com) and secondary antibody conjugated to a fluorochrome. After immunostaining coverslips were mounted in Mowiol mounting medium and observed under in a Zeiss Axioskop 40 fluorescence microscope equipped with an Axiocam HRC camera for image acquisition. For the bimolecular fluorescence complementation (BiFC) assay, isolated myofibers cultured in adhesion were transfected with the indicated plasmids using Lipofectamin LTX (Life Technologies), then treated as described [24] .
Western Blot and Coimmunoprecipitation Assay
Western Blot assays were performed as described previously [21] . When shown, the results were quantified by densitometry using ImageJ software. CoIP assays were performed as described previously [24] .
Transcription Reporter Assays
C2C12 and COS1 cells were cotransfected with pGL3(des-MEF2)3, pRSVb-gal, and the MEF2C expression vectors, then analyzed as described [24] . . Anti-pSer98 MEF2C and anti-pSer110 MEF2C were generated in rabbit using synthetic phosphorylated MEF2C peptides.
Plasmids pFLAG-MEF2Ca1 WT and 2SA are described in [21, 24] , pFLAG-MEF2Ca2 was a gift from Tod Gulick (Orlando). Lentiviral vectors encoding MEF2Ca1 WT and 2SA were generated by cloning the respective cDNAs in the pLENTI-CMV-RFP-2A-PURO (Abm, www.abmgood.com). Vectors encoding for HAtagged PIN1 protein and the plasmids used for BIFC assay were described in [24] .
RNA Extraction and RT-PCR
Total RNA was extracted from muscles using TRIzol Plus RNA Purification System (Ambion, Milan, Italy, www.thermofisher.com) or from SC using total RNA purification kit (Norgen Biotek, Thorold, ON, Canada, www.norgenbiotek.com). Reverse transcription was performed using SuperScript III (Life Technologies, Milan, Italy, www.thermofisher.com) and oligo dT (Life Technologies). The cDNA was amplified by semiquantitative PCR or quantified in qPCR. Primer sequences are available upon request. Real-Time PCRs were performed using SYBR green reagent (ThermoFisher, Milan, Italy, www.thermofisher.com) in the LightCycler Roche PCR machine.
Chromatin Immunoprecipitations
Chromatin immunoprecipitations were performed as previously described [21, 28, 29] . Five microgram of anti-MEF2 (C21 sc-313X, Santa Cruz) and anti-NFYB (GeneSpin, www.labome. com) antibodies were added to each IP and incubated overnight at 48C on a rotating wheel. DNAs were resuspended in TE buffer and quantitative real-time PCR was performed using SYBR green reagent (ThermoFisher) in the LightCycler Roche PCR machine. The relative sample enrichment was calculated with the following formula: 2DCtx22DCty, where DCt x 5 Ct input 2 Ct sample and DCt y 5 Ct input 2 Ct control Ab. Data have been shown as means of three independent experiments.
RESULTS

Expression and Activity of MEF2Ca1 in Primary Myoblasts
To elucidate the role played by the a1 domain of MEF2C in primary myoblasts, we first determined the dynamics of inclusion of a1/a2 exons in Mef2c transcripts during the myogenic progression of murine SC by semiquantitative PCR analysis. For this purpose, we used exon-specific or common primers, whose location is shown in Figure 1A and Supporting Information Fig. 1A . Both strategies show that the a2 exon is ubiquitously expressed in quiescent, proliferating and differentiated SC-derived myoblasts. Inclusion of the a1 exon, almost undetectable in quiescent SC, is enhanced in activated SC-derived primary myoblasts, both a1 and a2 exons are highly expressed in differentiating cells ( Fig. 1A and Supporting Information Fig. 1B ). To monitor the dynamics of a exon at the protein level, we cultured primary SC for 0, 48 and 72 hours on floating myofibers from EDL muscles and we performed double immunolabeling for SC specific markers and MEF2C using a generic anti-MEF2C and two a1 isoform-specific antibodies developed and/or characterized in our laboratory (Supporting Information Fig. 1C-G) . We show that, although all quiescent SC express MEF2C (n 5 9 mice, >200 cells/mouse) ( Fig. 1B day 0) , only MYOD positive-dividing and MYOGENIN (MGN) positive-differentiating cells ( Fig. 1C and 1D , days 2 and 3), express the a1 domain. We confirmed that 97% of SC on freshly isolated myofibers were quiescent, CAVEOLIN-1 positive (Supporting Information Fig. 1H ) [30] . Immunoblot analysis confirmed the presence of MEF2Ca1 protein in proliferating and differentiated C2C12 cells (Supporting Information Fig. 1I ). Next, we tested the function of MEF2Ca1 in SC myogenic progression by overexpression. As Mef2c transcripts have two additional alternatively spliced regions, b exon and g domain [31] [32] [33] (Fig. 1A , left panel), we investigated their expression in SC and found exclusive expression of the exon b BARUFFALDI, MONTARRAS, BASILE ET AL.
skipped isoform, whereas both g1 and g-variants are equally expressed (Supporting Information Fig. 1L ). Therefore, we decided to evaluate the activities of the a1 exon in a a11 bg1 context [24] . Freshly isolated SC were transduced with a lentiviral vector carrying RFP and mouse MEF2Ca1 cDNAs and their proliferation and differentiation potential were compared to those of control cells (schematized in Supporting Information Fig. 2A , >80% of RFP1 infected cells, Supporting Information Fig. 2B ). We observed a 38% increase in the capacity of the cells to proliferate, upon overexpression of Single myofibers isolated from extensor digitorum longus muscles were cultured in floating conditions and immunostained for MEF2C, PAX7, MYOD or MYOGENIN. MEF2C was detected with a general antibody (total) (B), or two isoform-specific antibodies (MEF2Ca1* and MEF2Ca1) (C and D). Bars, 50 lm. (E, F): Primary SC were transduced with either control EV or MEF2Ca1 coding lentiviruses. 48 hours later, nuclei were stained with DAPI (E), 72 hours later cells were immunostained for MYOGENIN (F) and counted. The number of control transduced cells was taken as one. Three independent experiments with duplicate samples were carried out for each measurement. Error bars represent SEM. *, p < 0.05. Abbreviations: EV, empty vector; MEF2C, myocyte enhancer factor 2C Rplp0, Ribosomal protein large P0; 2RT, nonreverse-transcribed RNA; 2RNA, reverse transcription mixture; SC, satellite cells. (Fig. 1E) . The ability of MEF2Ca1 to promote cell proliferation was also observed in nonmuscle cells such as NIH 3T3 mouse fibroblasts (Supporting Information Fig. 2C ) and colon cancer cells [17] . We used a similar approach to study the role of MEF2Ca1 overexpression on terminal differentiation. For that purpose, 3 days post-infection cells were fixed and immunostained for MYOGENIN. SC-derived myoblasts were kept subconfluent and in growth medium, to dissect the effect of MEF2C overexpression from that of density-dependent cell cycle exit. In these conditions we observed a 25% increase of MYOGENIN positive cells compared to controls (Fig. 1F) , suggesting that MEF2Ca1 up-regulation promotes differentiation in addition to the pro-proliferative effect described above.
Phosphorylation of Ser98 and Ser110: A Regulatory Switch
To gain insight into the molecular mechanisms responsible for switching-on alternatively the pro-proliferative and the prodifferentiative activities of MEF2Ca1, we focused our attention on two phosphoacceptor sites, Ser98 and Ser110, located in a1 domain, whose phosphorylation regulates MEF2C function in C2C12 myoblasts, allowing its association with PIN1, an inhibitor of muscle terminal differentiation ( Fig. 2A) [17, 24] . As a first step, we characterized the level of phosphorylation of MEF2Ca1 during differentiation of C2C12 cells with phosphospecific antibodies, that specifically recognize MEF2C phosphorylated on Ser98 (anti-pSer98) or Ser110 (anti-pSer110) (Supporting Information Fig. 2D ). We found that Ser98/110 are phosphorylated exclusively in myoblasts (Fig. 2B) . Next, we performed the same analysis in SC retained in their niche on isolated myofibers. Again we observed Ser98/110 phosphorylation in proliferating MYOD1 primary myoblasts (Fig. 2C , proliferation). As concern differentiation, we plated single myofibers on Matrigel: Ser98 and Ser110 phosphorylation was detected in MYOD1 proliferating SC-derived myoblasts (Fig. 2D , proliferation), but not in differentiating MYOGENIN1 cells (Fig. 2D , differentiation). Overall our data indicate that MEF2Ca1 phosphorylation on Ser98/110 is restricted to proliferating myoblasts and absent in terminally differentiated cells. To test how the phosphorylation of PIN1 binding sites in MEF2Ca1 could affect proliferation and/or differentiation of SC, we investigated its transcriptional potential in promoting the expression of different target genes: two immediate early genes, polo like kinase 2 (Plk2) and JunB and troponin C1 (TnnC1), a myogenic target. We found that MEF2Ca1 induced the expression of both Plk2 and JunB endogenous genes and that this activation depends on the presence of intact Ser98/110 phosphoacceptor sites, given that equivalent levels (Supporting Information Fig.  2E ) of the non-phosphorylatable 2SA mutant had no activity (Fig. 2E) . Conversely, the non-phosphorylatable 2SA mutant stimulated the expression of TnnC1 more efficiently (32-fold) than the pro-myogenic MEF2Ca2 isoform (28-fold) (Fig. 2E) . In order to investigate whether MEF2Ca1 directly regulates the transcription of Plk2 and JunB genes, we looked at putative MEF2 recognition elements (MREs) around their transcription start sites by bioinformatics approach. We found putative MREs in the regulatory regions of both genes (Supporting Information  Fig. 2F ). Chromatin Immunoprecipitation (ChIP) experiments, with chromatin from proliferating myoblasts, showed a significant enrichment of MEF2 binding over the control antibody in the Plk2 amplicon containing the predicted MRE. The anti-NF-YB antibody, which is able to recognize the CCAAT-binding factor NF-Y, was used as negative control antibody (Fig. 2F) . Oppositely, a significant percentage of input DNA was immunoprecipitated by the anti-NF-YB antibody, but not by the anti-MEF2, when qPCRs were performed with oligonucleotides specific for the JunB CCAAT-regulatory region (Supporting Information Fig. 2G) . These results suggest a direct involvement of MEF2Ca1 in regulating the transcription of Plk2 and an indirect role in JunB regulation, possibly through the regulation of other transcription factors. Overall our data indicate that phosphorylation of Ser98 and Ser110 inhibits the transcriptional potential of MEF2Ca1 toward muscle-specific genes, while boosting the activation, directly or indirectly, of cell-cycle related target genes. Coherently, the 2SA mutant is more transcriptionally active (two-fold) than the wild type MEF2Ca1 protein toward a myogenic luciferase reporter gene in muscle (Fig. 2G ) and nonmuscle cells (Supporting Information Fig. 2H ). These findings indicate a critical role for phosphorylation of Ser98 and Ser110 in a1-domain-mediated transcriptional activation of proliferation-versus differentiation-target genes, suggesting that this covalent modification is the molecular switch of the bi-modal activity of MEF2C in SC.
PIN1/MEF2C Interaction in Primary Myoblasts
Next we determined the role of the peptidyl-prolyl cys/trans isomerase PIN1 in modulating MEF2C function in SC. First, we observed that Pin1 transcripts are upregulated in proliferating SC-derived myoblasts by RT-PCR (Fig. 3A) and that all MYODpositive proliferating myoblasts express PIN1 by immunofluorescence on single myofibers (Fig. 3B) . To demonstrate that the MEF2Ca1/PIN1 interaction takes place in adult myoblasts, we used the BiFC approach [34] . To this end, MEF2Ca1 and PIN1 were fused to the amino-or carboxyl-terminal fragment of YFP, respectively, and transfected into SC-derived myoblasts, the fusion proteins Jun-YN and Fos-YC were used as positive controls (Fig. 3C, panels ii, Fig. 3D, panels v) . Coexpression of FLAG-tagged MEF2Ca1 and HA-tagged PIN1-YC in plated SC resulted in complementation of the YFP in the nucleus of MYOD positive proliferating SC (Fig. 3C, panels iii,  Fig. 3D, panels vi) . Given that adult myoblasts also express Mef2c transcripts including the a2 exon, we next investigated whether PIN1 distinguishes between the two isoforms by coimmunoprecipitation experiments in transfected COS cells. As shown in Figure 3E , we found that only MEF2Ca1 interacts with PIN1, unlike the muscle-specific MEF2Ca2 isoform, devoid of the Ser110 residue ( Fig. 2A) . Altogether our data indicate that the MEF2Ca1/PIN1 interaction might play a role in regulating the proliferative potential of adult myoblasts. To investigate this, equal numbers of freshly isolated adult SC were transduced with combinations of lentiviral vectors carrying PIN1 and/or MEF2Ca1 cDNAs, and their proliferation potential was assayed by evaluating the number of cells after 3 days in culture. We show that PIN1 and MEF2Ca1 synergize to promote proliferation, with an average 60% increase of cell number compared to control cells and about 15% increase versus MEF2Ca1 overexpressing cells (Fig. 3F) . These data indicate that association with PIN1 increases the proproliferative activity of MEF2Ca1 in primary myoblasts. To reinforce these observations, we used lentiviral vectors encoding MEF2Ca1 mutated in the PIN1 binding sites located in the 
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a1 exon (Ser98/110) and in the C-terminus (Ser254 and Ser388) [24] (SA mutant) and we evaluated the proliferation and differentiation potential of transduced SC. We found that the SA mutant is not able to efficiently stimulate myoblasts expansion (Fig. 3G ) but retains the ability to promote their differentiation, expressed as in increase of the percentage of MGN1 (50%) and TROPONIN T1 (TNT1) (60%) cells (Fig.  3G) . Thus, phosphorylation of the PIN1 binding sites 
Phosphorylation of the a1 Domain in Muscle Regeneration
We aimed to confirm the relevance of MEF2Ca1 phosphorylation in SC function in vivo during muscle regeneration. We first validated that this regulatory mechanism is active during skeletal muscle regeneration upon cardiotoxin (CTX)-induced injury. Western blot analysis showed that the expression level of the a1 domain increased in regenerating muscle at 2 days post-injury (p.i.) and, although it gradually decreased, it remained expressed throughout the course of regeneration (Fig. 4A, left and middle panels), together with a remarkable level of phosphorylation at Ser98/110 at 2 and 5 days p.i., a time frame concomitant with proliferation of activated SC (Fig. 4A, right panel) . Next we investigated the cellular source of MEF2C protein by immunofluorescence analysis on cryosections of regenerating TA muscles at 5 days p.i.: MEF2C protein is expressed in 100% of centrally located nuclei of newly formed myofibers and in 30% of mononucleated interstitial cells (Fig. 4B) . In summary our results indicate that the a1 domain is expressed throughout muscle regeneration and is subjected to a dynamic phosphorylation on Ser98/110, suggesting multiple roles played by MEF2Ca1 in vivo.
Effects of MEF2C Splice Variants Overexpression in Adult Muscle
To investigate the role of MEF2Ca1/a2 splice variants and of MEF2Ca1 phosphorylation in SC function in vivo, we performed a muscle regeneration assay. Due to the high functional redundancy of MEF2 proteins [7] , we decided to adopt a gain of function strategy. TA muscles were subjected to a single CTX injury and 2 days later they were injected with lentiviruses encoding the MEF2Ca splice variants and the mutant MEF2Ca1 protein or the RFP cassette alone. Muscles were analyzed 5 or 15 days later (as schematized in Supporting Information Fig. 3A) . Infection efficiency was >60%-70% for all vectors (Supporting Information Fig. 3B ) and qRT-PCR analysis confirmed the ectopic expression of transcripts encoding RFP and MEF2C (Supporting Information Fig. 3C ). Immunofluorescence analysis confirmed that MEF2C protein is expressed and phosphorylated on Ser98 in activated, DESMIN-positive SC (Supporting Information Fig.  3D ). Examination of serial sections of muscles overexpressing MEF2C proteins revealed an increase in the overall size throughout the body of the muscle that is particularly pronounced with the 2SA mutant at 15 days p.i. (Fig. 5A) . Evaluation of the cross-sectional areas (CSA) of regenerated muscles showed the presence of a number of hypertrophic myofibers, in muscles that overexpress all MEF2C proteins, in comparison to control injected muscles (Fig. 5B) . However, the hypertrophic effect is particularly pronounced upon ectopic expression of the non-phosphorylatable 2SA mutant, already at an early stage of regeneration (5 days p.i.). The upper panels of Figures 5B show the frequency distribution of myofiber CSA in the transduced regenerating muscles. ). At the 5-day time point regenerating muscle that overexpress MEF2Ca2 is instead characterized by a high proportion of smaller newly regenerating myofibers, with a shift of 280 lm 2 and 297,64 lm 2 of the mode and median CSA, probably due to the ability of this splice variant to promote myotube formation [16] .
Exclusively in the case of muscles overexpressing MEF2Ca1, at 15 days p.i., we observed the coexistence of hypertrophic fibers (>2400 lm 2 , 9% of totally counted myofibers) with small, regenerating ones (<200 lm 2 ) suggesting that, in addition to the hypertrophic effect, a regenerative process persists at a stage in which this process has normally ended. This observation suggest that MEF2Ca1 might stimulate SC proliferation also in vivo. To address this issue, we quantified the number of mononucleated interstitial cells expressing Ki67, a marker of proliferation, in transduced adult muscles 5 days p.i. In agreement with the in vitro data, we found that the percentage of Ki671 nuclei was increased in MEF2Ca1 (6.5%) compared to MEF2Ca2 overexpressing (5.38%) and control muscles (4.8%), whereas ectopic expression of the 2SA mutant (Fig. 5D ). Overall our findings indicate that both MEF2Ca1 and MEF2Ca2 splice variants promote muscle regeneration and hypertrophy in adult muscles. Furthermore, we present evidence indicating a bimodal activity of MEF2Ca1 for which the level of phosphorylation of the PIN1 binding sites tips the balance toward its ability to promote cell proliferation, differentiation and muscle growth.
Targets of Overexpressed MEF2C Splice Variants in Adult Muscle
As MEF2C modulates alternatively muscle-and proliferationrelated genes in a splice variant-and phospho-dependent manner in cultured myoblasts, we tested whether these regulatory mechanisms operate also in vivo. Indeed, qPCR analysis of RNA extracted from regenerated muscles (15 d.p.i.) showed that MEF2Ca1 overexpression promotes the expression of the immediate early gene Plk2 in adult muscle more efficiently than the 2SA mutant or the MEF2Ca2 splice variant, which in contrast are stronger activators of the muscle-specific gene TnnC1 (Fig. 6A) . In addition, we observed that both the MEF2Ca2 isoform and the 2SA mutant are powerful activators of the expression of insulin like growth factor 1 and 2 (Igf1 and Igf2), two stimulators of myogenesis by activating progenitor cell proliferation, terminal differentiation and muscle growth (Fig. 6B ). In line with these results, we observed an increase in the levels of MYOD and of P38, an inducer of terminal differentiation and of MHC, a myogenic marker, in muscles that overexpress the non-phosphorylatable MEF2Ca1 mutant and MEF2Ca2 (Fig. 6C) . These results suggest that, analogously to what observed in cultured SC, MEF2Ca1 controls distinct sets of target genes associated with early (myoblast proliferation) or late (terminal differentiation) stages of muscle regeneration in vivo through a Ser98/110-phosphorylation switch. Furthermore, we found that solely MEF2Ca2 is able to potently activate the expression of the cyclin-dependent protein kinases (CDK) inhibitor Cdkn1a (p21) gene, a MEF2 target gene required for cell cycle withdrawal of skeletal myoblasts, in accordance with its predominant myogenic role [16, [35] [36] [37] .
Next we investigated the pathway underlying the observed MEF2C-dependent muscle hypertrophy, focusing on the IGF-1 signaling cascade, a major regulator of skeletal muscle mass through the PI3K/AKT pathway [38, 39] . We, therefore, checked the activation of AKT/mTOR signaling in regenerating adult muscles overexpressing MEF2C proteins and we found that total protein levels of AKT1, mTOR and the ribosomal protein p70S6K S6 kinase (S6K) as well as the phosphorylation level of AKT were upregulated upon overexpression of MEF2Ca2 and the 2SA mutant compared to the wild type MEF2Ca1 protein and the control samples (Fig. 6D) . Noticeably, we observed that only the nonphosphorylatable 2SA mutant has the ability to increase the levels of phosphorylated S6K, a key step for the activation of protein synthesis [40] . We also evaluated the myonuclear number in the same samples by determining the number of nuclei within the dystrophin-stained sarcolemma and we observed an increase in myonuclear number in muscles overexpressing MEF2Ca2 (50%) and the 2SA mutant protein (60%) (Fig. 6E) . These data indicate that MEF2Ca1-dependent muscle hypertrophy is the result of both protein synthesis and myonuclear fusion and that phosphorylation of Ser98/110 negatively controls these functions.
DISCUSSION
Our major finding is that MEF2Ca1, a MEF2C splice variant, is a strong stimulator of skeletal muscle hypertrophic growth, an effect that depends on two mechanisms, including the activation of the anabolic AKT/mTOR pathway and its downstream target pS6K and the addition of new myonuclei via the proliferation and further fusion of SC-derived myoblasts to the adult myofiber. These different activities are alternatively switched-on by a dynamic phosphorylation of Ser98 and Ser110, two phosphoacceptor sites encoded by the alternative a1 exon, their phosphorylation is paramount in the control of the pro-proliferative function, given that substitution of these two phosphoacceptor sites with non-phosphorylatable Alanine residues represses the pro-proliferative activity and at the same time enhances the promyogenic and hypertrophic abilities of MEF2C. Previous studies have implicated MEF2 proteins in the control of adult skeletal muscle regeneration, where they activate the differentiation gene expression program [7, 8] . In this study we present evidence to suggest that MEF2C, in addition to the pro-differentiating function, mainly due to the MEF2Ca2 isoform, also promotes expansion of primary myoblasts, an activity exhibited by the MEF2Ca1 protein in a phosphorylation-dependent manner. On the basis of our results, we hypothesize that the pro-proliferative activity of MEF2Ca1 on SC is related to its ability to direct the expression of Immediate Early Genes, including, JunB, Plk2, which are to be added to other cycle-related genes that are regulated by MEF2 proteins in muscle [17, 41] and nonmuscle cells [42, 43] .
The observed MEF2Ca1-dependent upregulation of JunB is in line with the results of ChIP analyses performed by the Encyclopedia of DNA Elements (ENCODE) consortium in human cells, demonstrating that MEF2 binds to regions upstream of the JunB gene, suggesting a direct role of MEF2C in regulating this gene. We identified a putative MRE in the promoter region of the JunB gene, near one conserved CCAAT elements, however, in our experimental conditions, we have not detected a recruitment of MEF2 to the identified MRE in front of an efficient binding of the NFY transcription factor to its binding site localized in the same region. This data may then indicate an indirect role of MEF2Ca1 in regulating the expression of JunB, potentially through other transcription factors. Plk2 transcripts present a broad tissue distribution and have been also detected in mouse SC [44] . Our findings also show that MEF2 proteins directly bind to the putative MRE located in the upstream region from the transcription sites of Plk2 suggesting that MEF2Ca1 might actively regulate Plk2 transcription by binding to an active enhancer.
One process contributing to the pro-proliferative function of MEF2C in primary myoblasts is the phospho-dependent interaction with PIN1. In this study we show that PIN1 and MEF2C physically interact in primary myoblasts and we found not only that PIN1 inhibits myogenic differentiation [24] but also that this interaction synergistically stimulates their expansion. The use of phosphospecific antibodies allowed us to follow the in vivo kinetics of phosphorylation of the PIN1 binding sites in the a1 domain: we observed a strong phosphorylation at Ser98/110 within five days after injury, when the regeneration response is at its highest. Later on, during remodeling of regenerated muscle we found maintenance of MEF2Ca1 expression but we did not detect phosphorylation at the PIN1 binding sites, suggesting an important role for the dephosphorylated protein in late phases of adult myogenesis. Our in vivo studies revealed that ectopic expression of the non-phosphorylatable MEF2Ca1 mutant protein induces the expression of myogenic markers and of P38, whose activity is important for early phases of myoblast differentiation [45] [46] [47] [48] [49] and myocyte fusion [50] . However, the pro-differentiative activity of the 2SA mutant is less pronounced than that exerted by MEF2Ca2, which instead potently stimulates the expression of the CDK inhibitor p21 gene, a key event for cell cycle exit and myogenic terminal differentiation. Conversely we observed that the 2SA mutant robustly promotes a notable increase of the cross-sectional area of myofibers that correlates with the activation of the AKT/mTOR anabolic pathway and the phosphorylation of the downstream target S6K [40, 51, 52] and the concomitant increase in the number of myonuclei. Altogether our data suggest a model whereby MEF2C protein variants promote different stages of myogenesis, ranging from SC proliferation, terminal differentiation and myofiber growth. MEF2Ca1 stimulates muscle growth through two mechanisms, by controlling first SC proliferation when phosphorylated on the PIN1 binding sites, subsequently, upon dephosphorylation it stimulates myonuclear accretion and protein synthesis through activation of the mTOR/ S6K pathway (Fig. 6F) . In support for this model, fully regenerated muscles overexpressing MEF2Ca1 are characterized by the coexistence of hypertrophic as well as small newly formed myofibers and an increase of Ki67-positive cells and Plk2 expression, reflecting the pleiotropic function played by this protein. Given our data, dynamic phosphorylation of Ser98/110 plays a key role in adult myogenesis. Both Ser residues are predicted to be dynamically phosphorylated by proline-directed protein kinases, including CDKs and mitogen-activated protein kinases (MAPKs), a prediction supported by our finding that CDK6/Cyclin D1 phosphorylates MEF2C at Ser110 in vitro [17] and treatment of cultured cells with CDK6 inhibitors reduces MEF2C phosphorylation. Experiments directed toward the identification of these kinases are the matter of ongoing work. Although MEF2C has been already implicated in activation of genes that promote cardiac hypertrophy in response to IGF1 signaling, this is the first report of its implication in skeletal muscle hypertrophy [53] [54] [55] . We hypothesize that MEF2C indirectly activates the AKT/mTOR pathway by inducing an up-regulation of Igf1 and Igf2 gene expression. ChIP analyses performed by the ENCODE consortium demonstrate that MEF2 is bound to MEF2 sites located in the promoter as well in an upstream region of the Igf1 gene, suggesting a direct role of MEF2C in promoting the expression of this gene. Interestingly previous studies indicate that forced expression of IGF-I can induce Mef2c gene expression in muscle cells [56] . Our observations of a MEF2C-dependent induction of Igf1 gene expression suggest a positive-feedback loop underlying muscle growth [56] .
CONCLUSION
In general, our data demonstrate that MEF2C promotes muscle regeneration and growth at two cellular levels: by means of activating SC proliferation and differentiation to provide myonuclei to growing myofibers and through promotion of the IGF1/AKT anabolic signaling pathway in differentiated myofibers to increase muscle mass. The timely coordination of these activities in adult myogenesis is ensured by a molecular mechanism in which alternative splicing and phosphorylation finely regulate the activity of MEF2C. Our data supply preliminary evidence that modulating MEF2Ca1 function might be a valuable therapeutic strategy for muscle wasting therapies.
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